The role of Fraction Exhaled Nitric Oxide (FeNO) in asthma management: an Italian consensus statement on clinical and economic aspects
FeNO testing significantly improves asthma management by aiding in phenotyping, therapeutic strategy formulation, and monitoring. It enhances disease control, accelerates patient care, and offers economic benefits by reducing hospital admissions and treatment needs. However, practical and economic barriers can limit its adoption. Standardized test execution and result interpretation by specialists are essential for accurate patient management. The inclusion of FeNO assessment among exempt services for asthma patients would at last promote its equitable access.
Authors
- Simona Barbaglia
- Carlotta Galeone (ORCID: https://orcid.org/0000-0003-1934-5167)
- Umberto Restelli (ORCID: https://orcid.org/0000-0001-6831-3044)
- Mario Picozza (ORCID: https://orcid.org/0000-0002-2529-6456)
- Sofia Silvola (ORCID: https://orcid.org/0000-0002-9679-5164)
- Fabio Luigi Massimo Ricciardolo (ORCID: https://orcid.org/0000-0003-1826-5018)
- Mariagrazia Celeste
- Marco Bo (ORCID: https://orcid.org/0000-0003-0580-3227)
- Rosa Annibale
- Sabrina Ferri
- F Capano
- Pasquale Di Girolamo Faraone
- Matteo Bonini
Institutions
- University Carlo Cattaneo (IT)
- Federazione Nazionale Imprese Elettroniche ed Elettrotecniche (IT)
- ANT Foundation Italy Onlus (IT)
- Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli (IT)
- Policlinico Tor Vergata (IT)
- Ospedale San Luigi Gonzaga (IT)
- University of Milano-Bicocca (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Multidisciplinary Respiratory Medicine
- Published
- 2025-04-08
- DOI
- https://doi.org/10.5826/mrm.2025.1006
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- AstraZeneca
- Sanofi
- Grifols